Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control IOL Clear all
Completed Not applicable Interventional Results available

A Clinical Study of the ACRYSOF® IQ Extended Depth of Focus Intraocular Lens (IOL)

NCT03274986
View directory record Official record
Conditions
Cataract
Interventions
ACRYSOF® IQ Extended Depth of Focus IOL, ACRYSOF® IQ Monofocal IOL, Cataract surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
22 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Fort Collins, Colorado • Bradenton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Investigation of the Next Generation Intraocular Lens

NCT03500198
View directory record Official record
Conditions
Cataract
Interventions
Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL, Control Monofocal Intraocular Lens: TECNIS Monofocal IOL
Device
Lead sponsor
Johnson & Johnson Surgical Vision, Inc.
Industry
Eligibility
22 Years and older
Enrollment
247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
10
States / cities
Torrance, California • Bradenton, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Phase 2 Interventional

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

NCT03180255
View directory record Official record
Conditions
Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Interventions
Dexamethasone phosphate, Placebo
Combination Product · Other
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced Sep 6, 2026, 1:32 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

ACRYSOF® Restor Apodized Diffractive IOL Postmarket Evaluation of Clinical Outcomes and Life-Style Visual Performance RESTOR IOL SN60WF IOL (Control Group)

NCT00345111
View directory record Official record
Conditions
Refractive Assessment
Interventions
Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Not applicable Interventional Results available

EYEFILL® C. -US Viscoelastic Clinical Investigation

NCT02024711
View directory record Official record
Conditions
Cataract
Interventions
EYEFILL® C.-US Viscoelastic, Healon® Viscoelastic (CONTROL)
Device
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
22 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
Phoenix, Arizona • Redding, California • Cape Coral, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 6, 2026, 1:32 AM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

NCT07218783
View directory record Official record
Conditions
Cataract, Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL
Drug · Device
Lead sponsor
SpyGlass Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert

NCT04465864
View directory record Official record
Conditions
Glaucoma, Primary Open Angle, Cataract
Interventions
Intracanalicular Dexamethasone, 0.4 mg insert
Drug
Lead sponsor
Wolstan and Goldberg Eye Associates
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL

NCT01602068
View directory record Official record
Conditions
Cataract
Interventions
Dexamethasone Phosphate Ophthalmic, 100 mM Sodium Citrate Buffer
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Tamarac, Florida • Washington, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL.

NCT05372315
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Iworks Laser and Vision Center
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 6, 2026, 1:32 AM EDT
Terminated Phase 4 Interventional

Visual and Refractive Outcomes After Implantation of Aspheric IOLs With Different Dioptric Increments and Manufacturing

NCT01249144
View directory record Official record
Conditions
Cataract
Interventions
Intraocular Lens (IOL)
Device
Lead sponsor
Lenstec Incorporated
Industry
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Tarpon Springs, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

NCT00666211
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
educational intervention, Titrated pain management, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Hopkinsville, Kentucky • Owensboro, Kentucky • Chattanooga, Tennessee + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of a Small Aperture Extended Depth of Focus Intraocular Lens

NCT03633695
View directory record Official record
Conditions
Cataract, Presbyopia
Interventions
IC-8 IOL Group, Control Group
Device
Lead sponsor
AcuFocus, Inc.
Industry
Eligibility
22 Years and older
Enrollment
453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
21
States / cities
Tucson, Arizona • Bakersfield, California • Laguna Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

NCT00774930
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Lanreotide, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Los Angeles, California • Stanford, California • West Hollywood, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 6, 2026, 1:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

NCT06421636
View directory record Official record
Conditions
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Interventions
REGN7999, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 6, 2026, 1:32 AM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

NCT07218796
View directory record Official record
Conditions
Cataract, Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL
Drug · Device
Lead sponsor
SpyGlass Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 6, 2026, 1:32 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Outpatient Cervical Preparation to Reduce Induction Duration in NTSV Women

NCT03934918
View directory record Official record
Conditions
Cervical Ripening, Outpatient, Patient Satisfaction, Nulliparous, Length of Stay
Interventions
Treatment
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 6, 2026, 1:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long Term Outcomes of Vivity Intra Ocular Lens(IOL) Versus Control

NCT04561570
View directory record Official record
Conditions
Cataract
Interventions
Vivity ACRYSOF IQ IOL Group, ACRYSOF IQ IOL Control Group
Device
Lead sponsor
John Berdahl, MD
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Investigation of the TECNIS® Next-Generation Intraocular Lens

NCT06377514
View directory record Official record
Conditions
Cataracts
Interventions
Test IOL Model DEN00V, Control IOL Model DCB00
Device
Lead sponsor
Johnson & Johnson Surgical Vision, Inc.
Industry
Eligibility
22 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
9
States / cities
Bakersfield, California • Jacksonville, Florida • Sioux City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Phase 3 Interventional

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

NCT00006348
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ondansetron, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Not applicable Interventional Results available

Vision Performance Evaluation of TECNIS EYHANCE™ With TECNIS SIMPLICITY™ Compared to TECNIS® 1-piece Intraocular Lenses

NCT05025345
View directory record Official record
Conditions
Cataract
Interventions
Tecnis Eyhance, Tecnis 1 piece IOL
Device
Lead sponsor
Johnson & Johnson Surgical Vision, Inc.
Industry
Eligibility
22 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Bakersfield, California • Long Beach, California • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 6, 2026, 1:32 AM EDT
Completed Not applicable Interventional Results available

Investigation of the Safety and Effectiveness of a Trifocal IOL

NCT04176965
View directory record Official record
Conditions
Eye Diseases, Postcataract Aphakia, Cataract, Lens Opacities
Interventions
FINEVISION HP IOL, Alcon AcrySof SN60AT
Device
Lead sponsor
Beaver-Visitec International, Inc.
Industry
Eligibility
22 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
20
States / cities
Northridge, California • Orange, California • Orland Park, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 6, 2026, 1:32 AM EDT
Not yet recruiting Not applicable Interventional

Is Nipple Stimulation Effective for Inducing Labor and Acceptable to Patients, Nurses, and Providers?

NCT07588529
View directory record Official record
Conditions
Pregnancy, Induction of Labor
Interventions
Electric breast pump for nipple stimulation, induction of labor
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 6, 2026, 1:32 AM EDT
Enrolling by invitation Not applicable Interventional

Visual Outcomes in Patients Contralaterally Implanted With PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro

NCT07076277
View directory record Official record
Conditions
Cataract, Multifocal Intraocular Lens
Interventions
Clareon PanOptix Pro and Clareon Vivity Intraocular Lens, Clareon PanOptix Pro Intraocular Lenses
Device
Lead sponsor
Brian Shafer
Other
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Alexandria, Minnesota • Bozeman, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 6, 2026, 1:32 AM EDT